{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016061","form_type":"8-K","ticker":null,"cik":"0001300734","company_name":"SHINECO, INC.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.867776+00:00","generated_at":"2026-05-18T23:24:35.745496+00:00","sec_items":["2.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Shineco closes 51% acquisition of InfiniClone for ~$19.9M cash and 3.45M shares","bullets":["Acquired 51% equity in InfiniClone Limited from Dr. Lim Kah Meng.","Consideration: $19,895,600 cash plus 3,450,000 shares of common stock.","Shares issued under Regulation S; seller represented non-U.S. person status.","Financial statements and pro forma data to be filed within 71 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016061","json":"https://secwatch.observer/filing/0001641172-25-016061.json","markdown":"https://secwatch.observer/filing/0001641172-25-016061.md","text":"https://secwatch.observer/filing/0001641172-25-016061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1300734/000164117225016061/0001641172-25-016061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1300734/000164117225016061/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:24:35.745496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9f9017f017c36342ccdd7301368914ae6ade94b","claim":"SHINECO, INC. completed an acquisition involving Dr. Lim Kah Meng for US$19,895,600 in cash and 3,450,000 shares (closed 2025-06-18).","evidence_excerpt":"in InfiniClone to Shineco Life Science; therefore, InfiniClone became a direct subsidiary of Shineco Life Science. In exchange, Shineco Life Science paid to the Seller US$19,895,600 in cash and the Company issued 3,450,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”). The Shares were issued in reliance on Rule 902 of","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1300734/000164117225016061/0001641172-25-016061-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Dr. Lim Kah Meng"},{"label":"Consideration","value":"US$19,895,600 in cash and 3,450,000 shares"},{"label":"Closing","value":"2025-06-18"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}